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 Introduction 
 Noncutaneous melanomas are uncommon tumors 
and form a small fraction of tumors that develop from 
melanocytes  [1] . The majority are found in the uvea, the 
oronasal and genital mucosa  [2] . Most of them are char-
acterized by poor prognosis, difficult local control and 
high incidence for nodal and distant metastasis. Being 
rare tumors with typically late diagnosis and unsatisfac-
tory therapy, a standardized treatment algorithm for sys-
temic disease has not been developed for most of them 
yet.
 In recent years, molecular staging in cancer cells and 
detection of activating mutations in the tumor-signaling 
pathway have given new therapeutic target options for 
cutaneous melanoma. However, only few studies have re-
ported on the mutation status and effect of the new spe-
cific therapeutic agents in noncutaneous melanoma. This 
analysis reports the different genetic aberrations of tumor 
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 Abstract 
 Background: The optimal treatment algorithm for noncuta-
neous melanomas must yet be established.  Objective: To 
compare systemic treatment-relevant mutational status, 
metastatic pattern and response to systemic treatment in 
noncutaneous melanoma.  Methods: Retrospective single-
center study analyzing 64 noncutaneous melanoma pa-
tients treated between January 2006 and September 2013. 
 Results: c-KIT mutations were found exclusively in vulvovag-
inal melanoma (4/7). Overall status for NRAS and BRAF muta-
tions was low (1/7 and 0/21 detected mutations, respective-
ly). Seven out of 7 vulvovaginal and 6/13 sinonasal melano-
mas first metastasized to lymph nodes, whereas 18/22 ocular 
melanomas first metastasized to the liver. Response to sys-
temic treatment in vulvovaginal melanomas was best for 
imatinib with a disease control rate of 3/3 and overall for 
ipilimumab with a disease control rate of 3/10. Sorafenib was 
associated with adverse drug reactions (6/13) and poor re-
sults.  Conclusion: Noncutaneous melanomas show few tu-
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cells found in our collective, evaluates the distinct meta-
static patterns and compares the different therapeutic ap-
proaches and outcomes.
 Patients and Methods 
 This is a single-center retrospective data analysis of 64 noncu-
taneous melanoma patients approved by the local ethics commit-
tee (KEK-ZH No. 2014-0143). Patients with sinonasal, vulvovagi-
nal or ocular melanoma treated or aftercared at the Department of 
Dermatology of the University Hospital of Zurich between January 
1, 2006, and September 31, 2013, were analyzed. Data was collect-
ed based on the internal medical history charts system KISIM 
(CISTEC AG, Zurich, Switzerland). Patients were classified into 3 
subgroups (sinonasal/vulvovaginal/ocular) and evaluated with de-
scriptive statistics separately. Each group was analyzed for prima-
ry therapy, mutation status, localization of first metastasis and sys-
temic therapy response.
 The date and localization of the first distant metastasis were 
defined at the first scan where metastasis suspicion was reported. 
When multiple first metastases in different organs were detected 
within the same scan, all locations were listed. A CT scan after 3 
months of therapy was applied to determine treatment response. 
Response was graded in 4 classes according to standardized RE-
CIST criteria: complete response (CR; –100% of tumor mass), par-
tial response (PR; more than –30% of tumor mass), stable disease 
(SD; –30% up to +25% of tumor mass) and progressive disease 
(PD; more than +25% of tumor mass or new tumor lesions). The 
disease control rate is defined as the sum of CRs, PRs and SDs. Due 
to multiple serial therapies with different agents, the sum of used 
therapeutics surmounts the number of patients in tables for sys-
temic therapy. Mutational status (BRAF, NRAS, c-KIT) was deter-
mined by PCR and assessed routinely in previously collected tis-
sue. No additional mutation analysis was performed for the cur-
rent retrospective research project.
 Results 
 A total of 64 patients, 17 of them with sinonasal, 8 with 
vulvovaginal and 39 with ocular melanoma, were evalu-
ated.
 Sinonasal Melanoma 
 The median age of the 17 included sinonasal patients 
at first diagnosis was 69 years (range 44–91), and there 
was a minor predominance for the female gender of 10/17 
(58.9%). Recurrent nasal bleeding and persistent nasal 
obstruction were the most common symptoms. Tumor 
size reached from 1 up to 7.5 cm of longitudinal spread-
ing.
 As primary therapy, 16 out of 17 patients had surgery. 
One patient did not undergo surgery due to extended 
spreading. Endonasal resections were primarily per-
formed, whereof only one resulted directly in R0 resec-
tion. With repeat surgery, 6 additional R0 resections were 
achieved. Radiotherapy with an average total of 60–70 Gy 
was applied in those patients where R0 resection was not 
accomplished. In 1 case only, R0 resection was accompa-
nied by radiotherapy.
 Local recurrence was a problem independent of the 
therapeutic procedure; 8 of 9 (89%) patients with R1 and 
radiotherapy, as well as 5 of 6 (83%) patients with R0 re-
section and no additional adjuvant radiotherapy showed 
local recurrence. The patient who received adjuvant ra-
diotherapy in addition to R0 resection had no local recur-
rence. However, local tumor control did correlate linear-
ly neither with absence of metastasis nor with increased 
overall survival.
 Molecular tumor analysis was performed for 10 of 17 
patients. None of the analyzed sinonasal tumors were 
BRAF (0/10) or c-KIT (0/9) mutation positive. In 1 out of 
4 patients, NRAS mutation was detected ( table 1 ).
 Table 1.  Mutation status listed by melanoma subgroup
Mutation Sample number Mutated Wild 
type
Sinonasal
BRAF 10 0 10
NRAS 4 1 3
c-KIT 9 0 9
Vulvovaginal
BRAF 5 0 5
NRAS 2 0 2
c-KIT 7 41 3
Ocular
Uveal
BRAF 5 0 5
NRAS 1 0 1
c-KIT 2 0 2
Conjunctival
BRAF 1 0 1
NRAS 0 0 0
c-KIT 1 0 1
 Mutation status is listed by melanoma subgroup. Molecular tu-
mor analysis was performed for 10 of 17 sinonasal, 5 of 8 vulvo-
vaginal and 7 of 36 ocular melanoma patients. Mutational status 
(BRAF, NRAS, c-KIT) was determined by PCR and assessed rou-
tinely in previously collected tissue. No additional mutation anal-
ysis was performed for the current retrospective research project.
1 Two mutations involved exon 13 K642E, 1 exon 17 N822K 
and 1 exon 11 L576P.
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 Thirteen out of 17 (67.4%) patients developed metas-
tasis during the observation period after an average of 
14.5 months (range 0–52.6). Four (23.5%) patients al-
ready showed metastasis at the time of first diagnosis. Lo-
calization of first metastasis varied and was most fre-
quently observed in lymph nodes (46%), lungs (38%) 
and/or bones (31%;  table 2 ).
 Nine of the 13 metastatic patients received single or 
multiple systemic therapies, and 4 patients did not quali-
fy. When progression was noticed, further therapeutics 
were applied.  Table 3 shows the used systemic therapeu-
tics and their responses. Ipilimumab was given to 4 pa-
tients, was overall much better tolerated than sorafenib 
and showed 1 total clinical and radiological tumor remis-
sion in a patient with lung, liver, cecum and bone metas-
tases. This response was stable for over 12 months and 
still ongoing at the end of the study period. The most of-
ten prescribed therapeutic agent sorafenib (n = 6) showed 
a rather poor response and was highly associated with 
severe adverse side effects that led to therapy interruption 
in 4 of 6 cases (67%). However, response to sorafenib 
seemed not to be correlating with the treatment duration, 
as the only patient maintaining SD was able to take med-
ication (2 × 400 mg/day p.o.) merely for 10 days. The 
combined treatment with BRAF/MEK inhibitors [selec-
tive MEK inhibitor binimetinib (MEK162) 30 mg orally 
twice a day and panBRAF inhibitor RAF265 60 mg orally 
once a day] was given within a clinical trial to the NRAS-
mutated patient and led to SD after 3 months (NCT 
NCT01352273). Patients with sinonasal melanoma in 
this cohort showed a 1-year survival of 93.75% and a 
2-year survival of 75%.
 Vulvovaginal Melanoma 
 Eight patients with vulvovaginal melanoma were ana-
lyzed. The median age at first diagnosis was 62 years 
(range 55–75). Larger tumors caused itching or bleeding, 
smaller tumors were mostly diagnosed incidentally by gy-
necological routine control. The macroscopic diameter of 
6 measured tumors reached from 1 up to 4 cm, and thick-
ness ranged from 1.5 to 8 mm. Seven of 8 patients under-
went surgery for total excision. In 1 case, tumor size was 
too large for surgery, and due to the concomitant pres-
ence of lymph node metastasis, systemic therapy was ini-
tiated. In 5 of 7 (71%) cases, R0 resection was achieved at 
first surgery, 2 patients needed repeat surgery resulting in 
good local tumor control. In 5 out of 7 patients, sentinel 
lymph node biopsy was positive or lymph node metasta-
ses were radiologically detected at the time of surgery. In 
these patients, a subsequent lymph node dissection was 
performed. Additional adjuvant therapy was performed 
in 1 case only with systemic pegylated interferon for 5 
years (100 μg/week s.c.).
 Molecular tumor mutation analysis was performed in 
7 of 8 patients. Four samples were positive for c-KIT (4/7) 
mutations, containing 2 exon 13 K642E, 1 exon 17 N822K 
and 1 exon 11 L576P mutations, whereas no BRAF (0/5) 
or NRAS (0/2) mutations were found ( table 1 ).
 In all patients who developed metastasis during the 
study period (7/8), local lymph nodes were first affected 
( table 2 ).
 Six of 8 (75%) patients developed further distant me-
tastasis during the study period after a median period of 
24.3 months (range 0–104.8), 2 of them already at the time 
of first diagnosis. Applied systemic therapeutics and their 
responses are listed in  table 3 . Best responses were achieved 
with imatinib and ipilimumab, leading to PRs in 2/3 (66%) 
of cases for imatinib and 1/3 (33%) for ipilimumab. The 
anti-PD-1 antibody pembrolizumab (blinded 2 or 10 mg/
kg i.v. every 3 weeks, NCT01704287) was given only in 1 
case and led to SD after 3 months. Adjuvant treatment 
 Table 2.  Localization of first metastasis listed by melanoma sub-
group
Localization Frequency
Sinonasal (n = 13)
Lymph nodes 6 (46%)
Lung 5 (38%)
Bone 4 (31%)
Stomach 1 (8%)
Omentum 1 (8%)
Meningeosis carcinomatosa 1 (8%)
Vulvovaginal (n = 7)
Lymph nodes 7 (100%)
Ocular (n = 22)
Liver 18 (82%)
Lung 7 (32%)
Bone 5 (23%)
Lymph nodes 3 (14%)
Abdominal 2 (9%)
 The sum of listed metastasis localizations can surmount total 
patient number due to multiple simultaneous detections with the 
same scan. Localization of first metastasis is listed by melanoma 
subgroup. Frequency is listed in numbers and percentages illus-
trating the different metastatic pattern of the three different sub-
groups: sinonasal melanoma predominantly metastasize to lymph 
nodes and lungs, all vulvovaginal melanomas showed lymph node 
involvement first, whereas ocular melanoma mainly spread to the 
liver.
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with pegintron 100 μg/ week s.c. for over 5 years (includ-
ing nodal relapse during that time followed by lymph 
node dissection) showed a favorable course in 1 case as 
well, maintaining the patient disease free since then.
 Ocular Melanoma 
 Thirty-nine patients with ocular melanoma (36 uveal, 
3 conjunctival) were included into the study. The median 
age at first diagnosis was 62 years (overall range 28–93, 
uveal range 28–93, conjunctival range 61–81) with slight 
predominance for the female gender of 23/39 (60%). 
Most common symptoms were visual impairment or ret-
inal detachment for uveal and visible exterior color 
change for conjunctival melanoma. However, diagnosis 
occurred as incidental findings during ophthalmological 
routine examinations as well. Primary uveal melanoma 
treatment included enucleation (n = 19) or radiotherapy 
(n = 16, mainly proton beam therapy). One patient re-
fused therapy. Conjunctival tumors were addressed de-
pending on size and localization. One patient with a small 
limbal tumor partially spreading on the cornea under-
went a full nontouch conjunctival tumor excision includ-
ing resection of the corneal part in toto followed by topi-
cal 0.25% mitomycin application (33%). In the other 2 
(67%) cases, tumor extent was larger, and an exenteration 
had to be performed. All excisions were in sano.
 Table 3.  Systemic therapy and response listed by melanoma subgroup
Therapeutic agent Total 
number
OR or CR SD PD
Sinonasal
Ipilimumab 4 1 1 2
Imatinib 1 0 0 1
Sorafenib 6 0 11 51
BRAF/MEK inhibitor 1 1 0 0
Chemotherapy 6 0 1 5
Vulvovaginal
Ipilimumab 3 1 0 22
Pembrolizumab 1 0 1 0
Interferon pegintron 100 μg/week s.c. 1 0 1 0
Imatinib 3 2 1 0
Nilotinib 1 0 0 1
Chemotherapy 5 0 1 4
Ocular
Ipilimumab 3 0 0 3
Bevacizumab + paclitaxel + carboplatin 1 0 1 0
Sorafenib monotherapy 4 0 1 33
Sorafenib + paclitaxel 2 0 2 0
Sorafenib + cisplatin 1 0 0 1
Selumetinib 1 0 0 1
Sonidegib (LDE225) 1 0 0 1
Bortezomib + temozolomide 1 0 1 0
Dacarbazine 7 0 2 5
Vindesine monotherapy 2 0 1 1
Vindesine + cisplatin 2 1 0 1
Cisplatin monotherapy 1 0 0 1
Temozolamide monotherapy 1 0 0 1
Paclitaxel + liposomal doxorubicin 1 0 1 0
Taurolidine 1 0 0 1
Lomustine 1 0 1 0
 1 Four of 6 patients had to stop treatment due to severe cutaneous toxicity (palmoplantar erythrodysesthesia). 
2 One of 2 patients had to stop treatment due to severe adverse drug reaction (autoimmune colitis + sigma per-
foration, uveitis and otitis interna). 3 Two of 3 patients had to stop treatment due to cutaneous toxicity (palmo-
plantar erythrodysesthesia).
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 Four out of 16 (25%) uveal melanoma patients who 
received radiotherapy as primary treatment experienced 
local recurrence after an average of 43 months (range 24–
76). In contrast, local tumor recurrence in patients who 
underwent enucleation was not detected. Also, none of 
the 3 conjunctival melanoma patients showed local tu-
mor recurrence.
 Partial molecular tumor mutation analysis was per-
formed in 7 of 36 patients with uveal melanoma and for 
1 of 3 patients with conjunctival melanoma. No mutation 
was found for BRAF (0/5), NRAS (0/1) or c-KIT (0/2) in 
uveal melanoma, and the analyzed conjunctival tumor 
showed no mutation for BRAF or c-KIT either, with in-
definite NRAS mutation status ( table 1 ).
 In 22 (56%) patients (21 uveal, 1 limbal conjunctival 
primary tumor), metastasis was detected after a median 
period of 56.9 months (range 0–198.1). Two patients 
(uveal) already showed metastasis at the time of first di-
agnosis. The most frequent localization of first distant 
metastasis was the liver (82%), followed by the lungs 
(32%) and bones (23%;  table 2 ).
 Thirteen of the 22 patients with systemic disease qual-
ified for systemic therapy. Applied systemic therapeutics 
and their responses are listed in  table 3 . Seven patients 
received sorafenib as a mono- or combined therapy. 
Three (43%) of them showed SD after 3 months, and 4 
(57%) patients showed PD. Two of these 7 (29%) patients 
had to stop the treatment due to adverse drug events (cu-
taneous toxicity). Three patients received ipilimumab 
and showed PD. One patient received bevacizumab com-
bined with paclitaxel and carboplatin and showed SD af-
ter 3 months ( table 3 ).
 Discussion 
 Local Therapy 
 Our results highlight the difficult local tumor control 
in sinonasal melanoma with recurrence rates of up to 80–
90% in both R0 resected patients without additional ra-
diotherapy as well as R1 resected patients with subse-
quent radiotherapy. Whether R0 resected patients do 
benefit from additional radiotherapy is discussed contro-
versially  [3, 4] and needs to be evaluated in a larger study 
population. Recent studies also showed that primary 
multilocular sinonasal melanoma does exist and forms a 
subtype that is associated with unfavorable local control 
independently of the postoperative procedure  [5] . In con-
trast, local tumor control was better in vulvovaginal mel-
anoma (7/8). However, in 4/6 cases sentinel lymph node 
biopsy was positive and in 2/8 cases radiological nodal 
involvement was detected at the time of first diagnosis. 
This suggests that diagnosis is established at a later time 
point compared to other melanomas. In uveal tumors, 
radiotherapy has been shown to be a legitimate alterna-
tive to radical surgery with similar long-term results for 
metastasization and overall survival  [6, 7] . The selection 
of the treatment procedure has to be evaluated for every 
patient individually and is based on uveal localization, tu-
mor and patient characteristics  [8–10] . In our cohort, lo-
cal recurrence was lower for enucleation (0%; 0/22) than 
for radiotherapy (25%; 4/16). However, we did not distin-
guish between proton beam therapy, brachytherapy and 
radiotherapy, and interventions were spread over a large 
period of time. Other sources with larger populations re-
ported much lower recurrence rates of between 1 and 6% 
after 5 years for proton beam therapy as well as for brachy-
therapy with a noticeable improvement over the last two 
decades  [8, 11, 12] . In recent years, the tendency has 
therefore been towards favoring eye- and partial-vision-
conserving therapies. In conjunctival melanoma, the le-
sions arising de novo in contrast to arising from precur-
sor ones along with local extension and corneal infiltra-
tion are the most predictive risk factors for tumor 
aggressiveness and systemic spreading probability. Com-
plete surgical excision is the standard procedure and in 
cases of extensive involvement exenteration is necessary 
 [13] . Local recurrence after conjunctival excision is com-
mon and makes further subsequent local treatment nec-
essary  [13–15] .
 Tumor Mutations 
 In the analyzed tumor samples, c-KIT mutation was 
found in vulvovaginal melanoma in 4 of 7 scanned cases 
(57%) and was absent in sinonasal (0/9) or ocular mela-
noma (0/3). This is slightly higher than previously report-
ed data that reported c-KIT mutations in approximately 
20–40% of genital-mucosa melanomas and a much lower 
incidence in other mucosal melanomas  [16–21] . BRAF 
mutation was not found in any of the 3 subgroups (0/21, 
i.e. 0/10 sinonasal, 0/5 vulvovaginal, 0/6 ocular melano-
ma), whereas NRAS mutation was detected in 1 sinonasal 
melanoma (1/7, i.e. 1/4 sinonasal, 0/2 vulvovaginal, 0/1 
uveal) only. Zebary et al.  [22] reported in a study on 56 
cases similar low incidences of 4% for BRAF and c-KIT 
mutations and 14% for NRAS mutations in sinonasal 
melanomas. In ocular melanoma, the incidence of BRAF 
mutation varies strongly depending on the original tissue 
and localization. While BRAF mutation has been report-
ed to reach a rate of up to 50% for iris melanoma  [23] and 
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about 22–29% for conjunctival melanoma  [24, 25] , it is 
often absent in the more prevalent posterior uveal mela-
noma (choroidal)  [26, 27] . c-KIT mutation plays a minor 
role in ocular melanoma with low to absent incidences 
 [28] . In contrast, GNA11 and GNAQ mutations are 
found regularly in uveal melanoma and have been shown 
to contribute to the development of malignancy by acti-
vating the MAPK pathway. Current trials are investigat-
ing the therapeutic effectiveness of MEK and PKC inhib-
itors  [29] . Already routinely performed for uveal mela-
noma is the detection of chromosomal aberration 
(especially chromosome 3 loss and chromosome 8 gain) 
with high predictive value for prognosis in uveal mela-
noma and metastasization  [9, 30, 31] .
 Localization of First Metastasis 
 Sinonasal melanomas showed a heterogenic metastat-
ic spread. Vulvovaginal melanoma on the other hand 
showed all first metastases in locoregional lymph nodes/
vessels. In contrast, first metastases in ocular melanomas 
were found in the liver in more than 80% (18/22) of cases, 
which corresponds to the described organotropy for uve-
al melanoma metastasization  [32, 33] . However, com-
bined/isolated metastases were found in the lungs (32%) 
and bones (23%) as well. Metastatic spread is therefore 
clearly different depending on primary tumor localiza-
tion and has to be taken into account in tumor aftercare 
surveillance schemes. Damato et al.  [10] developed a sur-
vival prediction tool for uveal melanoma based on mul-
tiple metastasization risk factors of the primary tumor to 
adapt aftercare and screening to individual risk.
 Systemic Treatment 
 Immunotherapy 
 Overall 10 patients (4 sinonasal, 3 vulvovaginal, 3 oc-
ular melanoma) received the anti-CTLA-4 antibody ipi-
limumab 3 mg/kg, whereof 1 patient (1/10) with sinona-
sal melanoma achieved tumor CR (10%). Overall, tumor 
control was achieved in 3/10 (30%) patients (including 
CR, PR and SD). One (1/10) patient suffered from a se-
vere adverse drug reaction (colitis with sigma perfora-
tion, uveitis and otitis interna), and therapy had to be 
stopped early (10%). These results correlate with the pre-
viously reported response rates for immunotherapy in 
mucosal melanomas of 3–12% PR and 16–43% SD as 
well as the published severe adverse drug reaction inci-
dence  [34, 35] . Also, other authors described CR in single 
cases in mucosal and uveal melanoma  [35, 36] . For re-
sponse to ipilimumab in uveal melanoma though, differ-
ing more modest data have been reported lately. While 
two previous studies provided similar data in 82 and 34 
metastatic uveal melanoma patients treated with ipili-
mumab (PR rates of 2.6 and 5%, SD rates of 29 and 43.4%, 
respectively  [36, 37] , and 1 CR  [36] ), no CR or PR was 
achieved in a recent phase II study including 53 patients 
 [38] . Whether ipilimumab is considerably less effective 
in uveal melanoma compared to other noncutaneous 
melanomas needs to be investigated in further studies, 
but overall response seems to be similar as in cutaneous 
melanoma, and therefore ipilimumab should be consid-
ered a treatment in slow-growing noncutaneous mela-
noma.
 In this patient population, only 1 patient (vulvovaginal 
melanoma) was treated with the anti-PD-1 antibody 
pembrolizumab after ipilimumab failure. This treatment 
resulted in an SD after 3 months. Recently very promising 
results with this new checkpoint inhibition have been re-
ported in cutaneous melanoma  [39, 40] . It will be of great 
importance to consider anti-PD-1 antibodies in noncuta-
neous melanomas as well.
 Targeted Therapy 
 c-KIT mutations were found as expected in vulvovag-
inal melanomas only  [19, 21] . All 3 mutated patients with 
systemic disease (2 mutated in exon 13 K642E and 1 in 
exon 11 L576P) received the kinase inhibitor imatinib as 
systemic therapy. All 3 patients showed at least SD after 3 
months. This result corresponds with the response rates 
to imatinib treatment described by Hodi et al.  [41] with a 
PR rate of 53.8% and an SD rate of 23.1% for c-KIT-mu-
tated melanomas (n = 13, including 9 patients with c-KIT 
mutation in exon 11; other mutation sites included exon 
17 and exon 13). As reported by Schoenewolf et al.  [42] , 
remarkable regression of lung, liver and bone metastases 
was observed under treatment with imatinib. However, 
brain metastases developed under the treatment. The lack 
of therapy efficacy for metastatic brain lesions despite 
good overall systemic response has been reported for 
imatinib-sensitive tumors arising from melanocytes as 
well as from other origins and may partially be explained 
by limited drug penetration into the central nervous sys-
tem  [18, 43, 44] . Development of secondary resistances 
has been documented for imatinib-treated melanoma pa-
tients as well (after 3.5–4.7 months)  [45, 46] . Whether 
long-term efficacy could be improved by combining ima-
tinib with other new targeted therapy agents needs to be 
evaluated in future studies.
 Thirteen patients (6 sinonasal, 7 ocular melanoma) 
were treated with sorafenib monotreatment (10/13) or 
with a combined therapy (3/13). The response rate was 
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relatively low and did not necessarily correlate with treat-
ment duration. In contrast, the frequency of severe ad-
verse drug reaction was high and led to early therapy in-
terruption in 6/13 of cases (46%) due to the development 
of palmoplantar erythrodysesthesia, a common drug-
specific reaction  [47] . After 3 months of therapy, none of 
the patients showed PR, 4/13 (31%) SD (whereof 2 had 
combined therapy with paclitaxel) and 9/13 (69%) PD. 
These observations suggest that this agent might not be 
the optimal treatment choice for these patients. New 
promising data published by Carvajal et al.  [48] reported 
an improved outcome in metastatic uveal melanoma 
when treated with the MEK inhibitor selumetinib. In our 
study, only 1 patient with uveal melanoma and unknown 
mutation status was treated within a clinical trial and 
showed PD after 3 months.
 Cytokines and Chemotherapy 
 In our population 1 patient with vulvovaginal mela-
noma received adjuvant systemic subcutaneous interfer-
on therapy for over 5 years and showed a particularly 
good course. Large studies have examined the positive 
effect of adjuvant immunotherapy with systemic interfer-
ons in cutaneous melanoma and reported the highest 
benefit for patients with ulcerated primary tumor and 
only marginal lymph node infiltration  [49] . Since most of 
the mucosal melanomas are ulcerated and, especially in 
the vulvovaginal group, the majority of our patients 
showed microscopic lymph node infiltration, adjuvant 
interferon therapy might be beneficial. However, this 
must be evaluated in a larger cohort first.
 Chemotherapy was applied to slow down progression 
when target or immunotherapy was ineffective and tem-
porary SD was reached in some cases. As no curative ap-
proach can be taken with chemotherapy and the benefit 
on overall survival is marginal, it makes sense to choose 
potentially more effective therapies over chemotherapy 
until extended.
 Limitations 
 This study has potential bias due to its retrospective 
setting and to its small sample size. Moreover, the study 
period is limited over time and might have failed to cap-
ture important disease course changes outside of this ob-
servation window. In addition, it is not possible for this 
analysis setting to draw conclusions on the singular con-
crete treatment effect on overall survival. Finally, system-
ic treatment of melanoma experienced big paradigm 
changes during the time period (2006–2013) of this study. 
The data of this study have therefore only a relative sig-
nificance for today’s treatment options.
 Conclusion 
 Noncutaneous melanomas are rare, and this analysis 
gives a single-center overview of the different courses and 
treatments. Noncutaneous melanomas have a low pres-
ence of tumor-signaling pathway mutations and distinct 
metastasization patterns. Ocular melanomas are the most 
frequent noncutaneous melanomas and locally respond 
best to surgical and radiation treatment. Tumor muta-
tions differ in conjunctival, iris and posterior uveal mela-
noma, and further exploration of the molecular biology 
should be performed to find vision-sparing targeted 
treatments. Imatinib is a good treatment option in the 
quite commonly c-KIT-mutated vulvovaginal melano-
mas, whereas treatment with sorafenib is highly associ-
ated with severe palmoplantar erythrodysesthesia and 
subsequent therapy interruption. Immunotherapy seems 
to be effective in noncutaneous melanomas with similar 
responses as in cutaneous melanomas and is therefore a 
legitimate therapy option in slow-growing disease. This 
suggests that anti-CTLA-4 and more importantly anti-
PD-1 antibodies might hold promising responses for 
noncutaneous melanomas and should be evaluated in 
larger prospective studies.
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